Loading...
XJPX
4507
Market cap15bUSD
Sep 22, Last price  
2,640.50JPY
1D
-2.28%
1Q
3.71%
Jan 2017
-52.84%
Name

Shionogi & Co Ltd

Chart & Performance

D1W1MN
P/E
13.18
P/S
5.13
EPS
200.33
Div Yield, %
6.29%
Shrs. gr., 5y
-7.20%
Rev. gr., 5y
5.62%
Revenues
438.27b
+0.73%
196,389,000,000199,759,000,000214,268,000,000227,511,000,000278,502,000,000282,350,000,000267,275,000,000282,903,000,000289,717,000,000273,991,000,000309,973,000,000338,890,000,000344,667,000,000363,721,000,000333,371,000,000297,177,000,000335,138,000,000426,684,000,000435,081,000,000438,268,000,000
Net income
170.43b
+5.19%
22,735,000,00018,595,000,00025,064,000,00015,661,000,00038,625,000,00020,026,000,00027,101,000,00066,727,000,00041,831,000,00044,060,000,00066,687,000,00083,879,000,000108,866,000,000132,759,000,000122,193,000,000111,858,000,000114,185,000,000184,965,000,000162,030,000,000170,434,000,000
CFO
195.46b
+26.69%
16,885,000,00014,116,000,00015,619,000,00029,120,000,00052,901,000,00056,528,000,00054,724,000,00059,276,000,00079,496,000,00045,604,000,000102,290,000,000111,903,000,000129,790,000,000145,684,000,000131,940,000,000109,039,000,000102,068,000,000177,867,000,000154,284,000,000195,460,000,000
Dividend
Sep 29, 20250 JPY/sh

Profile

Shionogi & Co., Ltd. engages in the research, development, manufacture, and distribution of pharmaceuticals, diagnostic reagents, and medical devices in Japan. It offers Fetroja, a multidrug-resistant for gram-negative bacterial infection treatment; Xofluza, an influenza virus drug; and Tivicay for HIV treatment. It also develops Symproic for opioid-induced constipation treatment; S-120083 for Inflammatory pain; S-010887 for Neuropathic pain; S-117957 for Insomnia; sivopixant for Neuropathic pain, Sleep Apnea Syndrome, and Refractory/unexplainedchronic cough; S-637880 for Neuropathic Low Back Pain; Zuranolone for Depression; SDT-001 for attention-deficit/hyperactivity disorder patients; BPN14770 for Fragile X syndrome and Alzheimer's disease; and S-237648 and S-309309 for Obesity. In addition, the company develops ADR-001 for Decompensated liver cirrhosis; S-723595 for NASH; S-588410 for Esophageal and Bladder cancer; S-488210 for Head and neck squamouscell carcinoma; S-588210 for Solid tumor; S-222611 for Malignant tumor; S-770108 for Idiopathic pulmonary fibrosis; SR-0379 for Cutaneous ulcer; S-005151 for Stroke and Epidermolysis bullosa; S-531011 for Solid tumor; S-0373 for Spinocerebellar ataxia; and S-600918 and S-217622 for COVID-19, as well as S-555739 for Control of the aggravation of COVID-19. Further, it offers antibody test kits for COVID-19. Shionogi & Co., Ltd. has collaboration agreements with Nagasaki University, the National Institute of Infectious Diseases, and The Kitasato University to develop antimalarial drugs. The company was formerly known as Shionogi Shoten Co., Ltd. and changed its name to Shionogi & Co., Ltd. in 1943. Shionogi & Co., Ltd. was founded in 1878 and is headquartered in Osaka, Japan.
URL
https://www.shionogi.co.jp/
IPO date
May 16, 1949
Employees
5,680
Domiciled in
JP
Incorporated in
JP

Valuation

Title
JPY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑032024‑032023‑032022‑032021‑032020‑032019‑032018‑032017‑032016‑03
Income
Revenues
438,268,000
0.73%
435,081,000
1.97%
426,684,000
27.32%
Cost of revenue
176,616,000
259,893,000
277,790,000
Unusual Expense (Income)
NOPBT
261,652,000
175,188,000
148,894,000
NOPBT Margin
59.70%
40.27%
34.90%
Operating Taxes
31,215,000
37,708,000
35,836,000
Tax Rate
11.93%
21.52%
24.07%
NOPAT
230,437,000
137,480,000
113,058,000
Net income
170,434,000
5.19%
162,030,000
-12.40%
184,965,000
61.99%
Dividends
(48,698,000)
(43,876,000)
(36,142,000)
Dividend yield
2.55%
1.95%
2.03%
Proceeds from repurchase of equity
(10,000)
(75,182,000)
(49,539,000)
BB yield
0.00%
3.34%
2.78%
Debt
Debt current
3,464,000
2,867,000
3,014,000
Long-term debt
18,418,000
20,373,000
12,794,000
Deferred revenue
Other long-term liabilities
20,639,000
21,697,000
23,709,000
Net debt
(680,434,000)
(654,939,000)
(567,509,000)
Cash flow
Cash from operating activities
195,460,000
154,284,000
177,867,000
CAPEX
(52,103,000)
(12,693,000)
(37,187,000)
Cash from investing activities
(129,069,000)
5,922,000
(43,578,000)
Cash from financing activities
(51,919,000)
(126,853,000)
(88,837,000)
FCF
(37,967,000)
351,293,000
(139,945,000)
Balance
Cash
374,795,000
573,851,000
309,224,000
Long term investments
327,521,000
104,328,000
274,093,000
Excess cash
680,402,600
656,424,950
561,982,800
Stockholders' equity
1,410,504,000
1,104,428,000
1,169,746,000
Invested Capital
724,617,400
629,453,050
546,143,200
ROIC
34.04%
23.39%
21.14%
ROCE
18.56%
13.62%
13.37%
EV
Common stock shares outstanding
850,936
290,211
297,805
Price
2,246.00
-71.02%
7,750.00
29.66%
5,977.00
-20.62%
Market cap
1,911,202,256
-15.03%
2,249,135,250
26.36%
1,779,980,485
-80.40%
EV
1,231,340,256
1,611,432,250
1,234,303,485
EBITDA
282,585,000
193,511,000
166,059,000
EV/EBITDA
4.36
8.33
7.43
Interest
9,027,000
6,701,000
1,919,000
Interest/NOPBT
3.45%
3.83%
1.29%